Comfortage - AD Prevention Strategies

Comfortage - Integration of Biomarkers, Genetic and Clinical Risk Factors for AD Prevention Strategies

Study is Interventional, cross-sectional, clinical trial without drug and without device

Inclusion Criteria:

• subjective cognitive decline, defined as self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; normal performance on standardised cognitive tests adjusted for age, sex, and education; decline cannot be explained by psychiatric or other neurologic disease, medical disorder, medication, or substance use; no functional impact on daily life activities
• mild cognitive decline, defined as persistent decline in cognitive performance (in comparison with a previous status) reported by the subject or by an informed caregiver; or observed by change on longitudinal cognitive testing; cognitive performance below expected range for that individual based on cognitive test performance (adjusted for age, sex, and education); performs daily life activities independently (but cognitive difficulty may result in detectable but minimal functional impact on the more complex activities of daily life, either self-reported or corroborated by a study partner); Clinical Dementia Rating Scale = 0.5
• Ability to sign and understand the informed consent form

Exclusion Criteria:

• Age under 50 or over 85 years
• Non-native Italian speakers
• Non degenerative and secondary forms of dementia
• Previous or current participation in clinical trials with anti-amyloid agents